Autopsy report · NCT07085468

A Study of LY3549492 in Healthy Weight Adult Participants

“Study terminated for strategic business reasons”

The sponsor’s own words in the registry.

Life of this trial

• Ran for about 1 month before it stopped.
• 1 participant enrolled.
• Results were posted on the registry 1 year 1 month after it ended.

Vital statistics

Status

Terminated

Phase

Phase 2

Sponsor

Eli Lilly and Company

Sponsor type

Industry

Conditions

Healthy

Interventions

LY3549492; Placebo

Participants

1

Sites

21

Countries

Canada, United States

Trials that died the same way

• The Efficacy and Safety of SerpinPC in Participants with Severe Hemophilia a or Moderately Severe to Severe Hemophilia B
  “Study terminated due to business and strategic decision” (96% match in meaning)
• A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of BFKB8488A Compared With Placebo in Participants With Non-Alcoholic Steatohepatitis
  “The study was terminated due to strategic business reasons.” (95% match in meaning)
• A Safety Study of PF-08046045/SGN-35T in Adults With Advanced Cancers
  “Study terminated as part of strategic considerations” (92% match in meaning)
• Phase I/II Dose-escalation Study to Investigate Safety and Pharmacokinetics/ Pharmacodynamics of WX-554 in Patients With Solid Tumours
  “Study terminated for business reasons” (91% match in meaning)
• Naxitamab and Granulocyte-Macrophage Colony Stimulating Factor (GMCSF) and Isotretinoin for Consolidation of Patients With High-Risk Neuroblastoma in First Remission.
  “Study terminated due to business priorities” (90% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.